Skip to content

Avandia Poses risk of Heart Attack and Other Heart Disease

FDA informed healthcare professionals of a potential safety issue related to Avandia (rosiglitazone). An on-going analysis of safety data for the treatment of type 2 diabetes mellitus using Avandia showed differing rates of ischemic cardiovascular events including heart attack or heart-related adver

Avandia Poses risk of Heart Attack and Other Heart Disease
Published:

FDA informed healthcare professionals of a potential safety issue related to Avandia (rosiglitazone). An on-going analysis of safety data for the treatment of type 2 diabetes mellitus using Avandia showed differing rates of ischemic cardiovascular events including heart attack or heart-related adverse events, some fatal, relative to other drugs used to treat diabetes.  The clinical studies reviewed to date vary with respect to their populations, treatment regimens, and length of follow-up.  Based on these data, the risk of ischemic cardiovascular events due to Avandia remain unclear.  Prescribers should continue to carefully make individualized treatment decisions for patients with diabetes mellitus.

View the official FDA press release here:
http://www.fda.gov/bbs/topics/NEWS/2007/NEW01636.html

Tags: Health

More in Health

See all
Netflix Documentary Highlights Family’s CRPS Struggles

Netflix Documentary Highlights Family’s CRPS Struggles

/
Can Stem Cells Help Treat CRPS?

Can Stem Cells Help Treat CRPS?

/

More from The Legal Examiner

See all
Do I Have CRPS/RSD? How to Tell

Do I Have CRPS/RSD? How to Tell

/
Former ER Doctor Spreads the Word: CRPS is Real

Former ER Doctor Spreads the Word: CRPS is Real

/